 | • レポートコード：B-MOR-040910 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、避妊薬および避妊具の世界市場について調べ、避妊薬および避妊具の世界規模、市場動向、市場環境、避妊法別（避妊手術、ピル、インプラント、注射、子宮内避妊リング（IUD）、コンドーム、女性用避妊具、ナチュラル避妊具）分析、投与経路別（経口、局所避妊具、注射）分析、器具別分析、性別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・避妊薬および避妊具の世界市場インサイト ・避妊薬および避妊具の世界市場環境 ・避妊薬および避妊具の世界市場動向 ・避妊薬および避妊具の世界市場規模 ・避妊薬および避妊具の世界市場規模：避妊法別（避妊手術、ピル、インプラント、注射、子宮内避妊リング（IUD）、コンドーム、女性用避妊具、ナチュラル避妊具） ・避妊薬および避妊具の世界市場規模：投与経路別（経口、局所避妊具、注射） ・避妊薬および避妊具の世界市場規模：器具別 ・避妊薬および避妊具の世界市場規模：性別 ・避妊薬および避妊具の世界市場：地域別市場規模・分析 ・避妊薬および避妊具の北米市場規模・予測 ・避妊薬および避妊具のアメリカ市場規模・予測 ・避妊薬および避妊具のヨーロッパ市場規模・予測 ・避妊薬および避妊具のアジア市場規模・予測 ・避妊薬および避妊具の日本市場規模・予測 ・避妊薬および避妊具の中国市場規模・予測 ・避妊薬および避妊具のインド市場規模・予測 ・避妊薬および避妊具の韓国市場規模・予測 ・関連企業情報・競争状況 |
The Global Contraceptive Drugs and Devices Market was valued at USD 21.1 billion in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period (2018 – 2023). China being the world’s most populated country has around 1.36 billion population and has one of the highest rates of contraceptives use.
Unintended pregnancies growing at a faster pace
Not using of the contraceptives or the incorrect use of the contraceptives may result in unintended pregnancies and the number of unintended pregnancies percentage is higher in the teens younger than 18 years, followed by the age group of 20-24 years. In the United States, the proportion of pregnancies that were unintended increased slightly between 2001 and 2008 (from 48% to 51%), but, by 2011 it decreased to 45%. And in 2014, these contraceptives have helped women to avoid 2 million unintended pregnancies, which would likely have resulted in 900,000 unplanned births and nearly 700,000 abortions. However, over past few years the awareness on contraception has contributed to both decline in unplanned pregnancies and also growth in the usage of the contraceptives market.
There are also other factors which are accelerating the growth of the contraceptives market is the increasing incidence of the STDs and the rapid increase in the population. The government initiatives are also promoting the use of contraceptives to avoid the unnecessary births and the health benefits from using the contraceptives have also been significant players in the growth of this market.
High cost of IUD (Intrauterine devices)
The high costs of the IUD devices have been a barrier for many of the women’s as IUDs are very expensive primarily because of the procedures involved which is known as implanting. The normal cost to insert or remove IUD is around USD 150 to USD 250, depending on the service. The IUD choice of method may not be chosen often because of the cost, which acts as a major restrain to the market growth.
The other major reason for the high cost is the relative length of the efficacy of the IUDs and as they last for a longer duration for years so their cost tends to be higher. There are also other factors such as religious and cultural opposition in certain emerging nations and the fear of certain issues such as infertility resulting from the use of contraceptives have been major setbacks from the market point of view which have been restraining the growth of this market.
North America holds the largest market share for contraceptive drugs and devices
In North America, over 90% of the female population uses the modern contraceptive techniques. The use of contraceptives is the highest in North America, whose share is estimated to be 75.4%. Following North America, Europe is the second largest market globally and the preference of the contraceptives generally varies by region.
According to the study by the United Nations, sterilization is the ideal method of contraception in India, while condoms are in the preferred choice in Japan. For instance, of the overall contraceptives available, the use of oral contraceptive pills is higher in Europe, while the use of IUD was higher in Asia.
Key Developments in the Market
• November, 2017: Teva Pharmaceuticals has signed an agreement with CooperSurgical which will acquire PARAGARD (intrauterine copper contraceptive), a product.
• July, 2017: Teva Pharmaceutical has announced the launch of Vagifem 1 (estradiol vaginal inserts), 10 mcg in the US.
Key players: BAYER HEALTHCARE AG, MERCK & Co., CHURCH & DWIGHT Co. Inc., WARMER CHILCOTT COMPANY Inc., AGILE THERAPEUTICS Inc., PFIZER, BIOSANTE PHARMACEUTICALS, MAYER LABORATORIES Inc., PANTARHEI BIOSCIENCE B.V. and TEVA PHARMACEUTICAL INDUSTRIES Ltd.
Reasons to Purchase this Report
• Current and future contraceptive drugs and devices market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES ANALYSIS
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING INCIDENCE OF THE STDS
6.1.2 INCREASING RATE OF UNINTENDED PREGNANCIES
6.1.3 EFFECTIVE CONTRACEPTION AND LESS SIDE EFFECTS OF IUCD
6.1.4 RISE IN GOVERNMENT INITIATIVES AND PRIVATE FIRMS TO PREVENT UNWANTED ABORTIONS AND PREGNANCIES
6.2 MARKET RESTRAINTS
6.2.1 HIGH COST OF TREATMENT
6.2.2 STRINGENT REGULATORY AND REIMBURSEMENT POLICIES
6.2.3 RELIGIOUS AND CULTURAL OPPOSITION TOWARDS IUDs
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 SEGMENTATION-BY CONTRACEPTIVE METHOD
7.1.1 STERILIZATION
7.1.2 PILLS
7.1.3 IMPLANTS
7.1.4 INJECTABLE
7.1.5 INTRAUTERINE DEVICE (IUD)
7.1.6 MALE CONDOMS
7.1.7 VAGINAL BARRIER METHODS
7.1.8 NATURAL PRODUCT
7.2 BY MODE OF DELIVERY
7.2.1 ORAL CONTRACEPTIVES
7.2.2 TOPICAL CONTRACEPTIVES
7.2.3 CONTRACEPTIVE INJECTABLE
7.3 BY DEVICE
7.3.1 CONDOMS
7.3.2 DIAPHRAGMS
7.3.3 CERVICAL CAPS
7.3.4 SPONGES
7.3.5 VAGINAL RINGS
7.3.6 IUD
7.3.7 IMPLANTS
7.4 BY GENDER
7.4.1 MALE
7.4.2 FEMALE
7.5 SEGMENTATION-BY GEOGRAPHY
7.5.1 NORTH AMERICA
7.5.1.1 UNITED STATES
7.5.1.2 CANADA
7.5.1.3 MEXICO
7.5.2 EUROPE
7.5.2.1 FRANCE
7.5.2.2 GERMANY
7.5.2.3 UNITED KINGDOM
7.5.2.4 ITALY
7.5.2.5 SPAIN
7.5.2.6 REST OF EUROPE
7.5.3 ASIA-PACIFIC
7.5.3.1 CHINA
7.5.3.2 JAPAN
7.5.3.3 INDIA
7.5.3.4 AUSTRALIA & NEW ZEALAND
7.5.3.5 SOUTH KOREA
7.5.3.6 REST OF ASIA-PACIFIC
7.5.4 MIDDLE EAST & AFRICA
7.5.4.1 GCC
7.5.4.2 SOUTH AFRICA
7.5.4.3 REST OF THE MIDDLE EAST & AFRICA
7.5.5 SOUTH AMERICA
7.5.5.1 BRAZIL
7.5.5.2 ARGENTINA
7.5.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS & ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. KEY PLAYERS
9.1 BAYER HEALTHCARE
9.2 PFIZER
9.3 MERCK & CO.
9.4 TEVA PHARMACEUTICALS, LTD.
9.5 AGILE THERAPEUTICS
9.6 ACTAVIS PLC
9.7 ANI PHARMACEUTICALS, INC.
9.8 CHURCH & DWIGHT, CO. INC.
9.9 FUJI LATEX CO., LTD
9.10 JOHNSON & JOHNSON, LTD
9.11 OTHERS
10. FUTURE OF THE MARKET